Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody–drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.

霍奇金淋巴瘤是一种治愈率很高的疾病。尽管大多数患者在一线治疗后获得完全缓解，但关键的未满足临床需求仍然存在，包括复发/难治性疾病、治疗相关发病率、生活质量受损和 60 岁以上患者预后不良。将检查点抑制剂和抗体药物偶联物等新型疗法纳入一线环境、序贯方法以及进一步的个体化治疗强度可能会满足这些需求。我们总结了经典霍奇金淋巴瘤患者当前的治疗选择，从一线治疗到同种异体造血干细胞移植，并描述了该领域的新试验。